You can buy or sell Inozyme Pharma and other stocks, options, and ETFs commission-free!
Inozyme Pharma engages in the research and development of novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Its lead product candidate is INZ-701, which is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
52 Week High
52 Week Low
— per share
Expected May 13, Pre-Market